



Akums

Namashkaar!

नमस्कार

**Light Within Us
Bows To The
Light Within You**



Our New Product offering



General - Oral solid Tablet / Capsule / Sachet /
Softgaltin capsule

Exhibit Batches Manufacturing & Stability On going



S.No	Products Name	Strength	Dosages Form	Therapeutic class	Innovator Details	API grade use in Exhibit batches	Dossier ready Status
1	Rivaroxaban	10 mg /15 mg /20 mg /2.5 mg	Tablets	Anticoagulant	XARELTO 2.5 mg/ 10 mg/ 15 mg/ 20 mg film-coated tablets	CEP Grade	Dossier ready for Europe / UK Market/Canada Market
2	Dapagliflozin	5 mg / 10 mg	Tablets	Antidiabetic	FORXIGA TABLET 5 mg and 10 mg	ASMF Grade	Dossier ready for Europe / UK Market/Canada Market
3	Dapagliflozin+ Metformin XR	10+1000mg/ 10+500mg/ 5+1000mg	Tablet	Antidiabetic	XIGDUO XR 10MG/1000MG Tablets/ 10MG/500MG Tablets/ 5MG/1000MG Tablets	ASMF Grade	Dossier ready for Europe / UK Market/Canada Market
4.	Sacubitril and Valsartan	24 mg + 26 mg/ 49 mg + 51 mg /97 mg + 103 mg	Tablet	Antihypertensive	ENTRESTO®24 mg/26mg /49mg/51mg /97mg/103mg (Bio-Strength)	CEP Grade	Dossier will ready by March-2026 for Europe / UK /Canada Market
5.	Tofacitinib	5 mg /10 mg	Tablets	Analgesics	XELJANZ 5 mg/10 mg	ASMF Grade	Dossier will ready by April/ May 2026 for Europe /UK / Canada Market
6.	Tofacitinib	11mg/22 mg	Tablets	Analgesics	XELJANZ XR 11mg XELJANZ XR 22 mg	ASMF Grade	Dossier will ready by Q4 2026 for Europe /UK / Canada Market
7.	Bempedoic Acid	180 mg	Tablets	Lipid-lowering drug	Nilemdo 180mg film-coated tablets	ASMF Grade	Dossier will ready by May /June 2026 for Europe /UK / Canada Market

Products which are subject to patent protection are currently not offered or made available in countries where patent are in force.

Exhibit Batches Manufacturing & Stability On going



S. No.	Products Name	Strength	Dosages form	Therapeutic class	Innovator details against we have conduct bio Studies	Product Current Status
8.	Empagliflozin & Linagliptin	10 mg/5 mg & 25 mg/5 mg	Tablets	Antidiabetic	Glyxambi 10 mg/5 mg & 25 mg/5 mg film-coated tablets	Dossier will ready by July/Aug 2026 for Europe /UK / Canada Market
9.	Linagliptin & Metformin	2.5 mg/850 mg 2.5mg/1000mg 2.5 mg/500 mg	Tablets	Antidiabetic	Jentaducto 2.5 mg/850, 2.5 mg/1,000 mg , 2.5 mg/500 mg mg film-coated tablets	Dossier will ready by July/Aug 2026 for Europe /UK / Canada Market
10.	Bempedoic Acid with Ezetimibe	180 mg & 10mg	Tablets	Lipid Lowering drug	Nustendi 180mg/10mg film-coated tablets	Dossier will ready by July/Aug 2026 for Europe /UK / Canada Market
11.	Empagliflozin	10 mg & 25 mg	Tablets	Antidiabetic	Jardiance 10 mg/25 mg film-coated tablets	Dossier will ready by July/Aug 2026 for Europe /UK / Canada Market
12.	Empagliflozin & Metformin film coated Tablets	5/850, 5/1000 mg, 12.5/850 and 12.5/1000 mg	Tablets	Antidiabetic	Synjardy 5 mg/850 mg film-coated tablets Synjardy 5 mg/1,000 mg film-coated tablets Synjardy 12.5 mg/850 mg film-coated tablets Synjardy 12.5 mg/1,000 mg film-coated tablets	Dossier will ready by July/Aug 2026 for Europe /UK / Canada Market
13.	Rivaroxaban	20 mg	Capsule	Anti-coagulations	Rivaroxaban Clonmel 20 mg hard capsules	Dossier will ready by July/Aug 2026 for Europe /UK / Canada Market
14.	Diclofenac	50mg	Oral Solution Sachets	Pain relief & inflammations	Voltfast/Nigfast	Dossier will ready by July/Aug 2026 for Europe /UK / Canada Market

Products which are subject to patent protection are currently not offered or made available in countries where patent are in force.

Our New Product Pipeline



S. No.	Products Name	Strength	Dosages form	Therapeutic class	Product Current Status
15.	Methamine Hippurate	1000mg	Tablet-	Anti-infectives.	Dossier will ready by Q4 26 for Europe /UK / Canada Market
16.	Ezetimibe tablets	10 mg	Tablets	Cholesterol-lowering medications	Dossier will ready by Q4 26 for Europe /UK / Canada Market
17.	Rosuvastatin and Ezetimibe	10 mg and 10 mg	Tablets	Treat high cholesterol and reduce the risk of cardiovascular disease.	Dossier will ready by Q4 26 for Europe /UK / Canada Market
18.	Trazodone HCl Sustained-release	75 mg	Tablets	Serotonin receptor antagonists and reuptake inhibitors (SARIs) class of antidepressants.	Dossier will ready by Q4 26 for Europe /UK / Canada Market
19.	Sodium Valproate SR	500 mg	Tablets	Antiepileptic medication	Under R&D development
20.	Ozanimod Hydrochloride	0.23 mg 0.46 mg 0.92 mg	Capsules	Relapsing Multiple Sclerosis (MS) and inflammatory bowel disease	Under R&D development
21.	Fidaxomicin	200 mg	Tablets	macrolide antibiotics	Under R&D development
22.	Finerenone	10 mg & 20 m	Tablets	chronic kidney disease	Kerendia
23.	Sulodexide	250 LSU	capsule	Treatment of thrombosis	SULODEXIDE MYLAN GENERICS

Products which are subject to patent protection are currently not offered or made available in countries where patent are in force.

Our Product Pipeline - US OTC Products



S.No.	Product Name	Dosages Form	Current Status
1.	Acetaminophen 325 mg, Dextromethorphan Hydrobromide 10mg, Phenylephrine Hydrochloride 5 mg Liquid filled soft Gel capsules (Daytime Cold & Flu liquid filled gel)	soft Gel capsules	6 M Stability sample evaluation (LDPE bag)
2.	Acetaminophen 325 mg, Dextromethorphan Hydrobromide 15mg, Doxylamine succinate 6.25 mg Liquid filled soft Gel capsules (Night Time Cold & Flu Liquid Gel)	soft Gel capsules	6 M Stability sample evaluation (LDPE bag)

Products which are subject to patent protection are currently not offered or made available in countries where patent are in force.

Our Product Pipeline - Orphan Drugs



S.No	Product Name	Dosages Form	Therapeutic class	Current Status	Indication
1	Ivacaftor 150 mg	Tablet	Anti Cancer	Under R&D Development	Cystic Fibrosis
2	Ivacaftor granules 25/50 75 mg	Sachet	Anti Cancer	Under R&D Development	Cystic Fibrosis
3	Eliglustat Tartrate	Capsules	Enzyme inhibitor	Prototype developed	for the long-term treatment of type 1 Gaucher disease
4	Nitisinone	Dispersible Tablet	HPPD inhibitor	Product developed in R&D, to be charged in stability	hereditary tyrosinemia type 1
5	Trientiene tetrahydrochloride	Capsules	Chelating agent	Product developed in R&D, charged in stability	Wilson's disease (hepatolenticular degeneration)

Products which are subject to patent protection are currently not offered or made available in countries where patent are in force.

Our Product Pipeline - Orphan Drugs



S.No.	Product Name	Dosages Form	Therapeutic class	Current Status	Indication
6	Carglumic acid	Tablet	Cholinergic Agonist	Under R&D Development	hyperammonemia in patients with a deficiency in N-acetyl glutamate synthase
7	Edaravone	Oral Suspension	Antioxidants	Under R&D Development	to treat amyotrophic lateral sclerosis
8	Edaravone	Injection	Antioxidants	Under R&D Development	to treat amyotrophic lateral sclerosis
9	Fenfluramine Hydrochloride	oral solution	Appetite-suppressant	Under R&D Development	seizures in children from 2 years of age and older with Dravet syndrome
10	Diazoxide	oral suspension	Antihypertensive	Under R&D Development	used to manage symptoms of hypoglycaemia (low blood sugar) that is caused by pancreas cancer, surgery, or other conditions.

Products which are subject to patent protection are currently not offered or made available in countries where patent are in force.

Our New Product Development On going



Oral Liquid

Exhibit Batches Manufacturing & Stability On going



S. No.	Products Name	Strength	Dosages form	Innovator details against we have conduct bio Studies	Product Current Status
1.	Nystatin	100000IU/ml	Oral Solution	Nystimex Mfg. by. Recipharm Parets SL, Spain	Dossier will ready by Q3 26 for Europe /UK / ROW Market
2.	Melatonin	1 mg / ml	Oral Solution	Melatonin 1mg/ml Oral Solution Mfg. by. Aspire Pharma Limited, UK	Dossier will ready by Q3 26 for Europe /UK / ROW Market

Products which are subject to patent protection are currently not offered or made available in countries where patent are in force.



Namaste

The light within us bows to
the Light within you

Thank You